Medicines Company gets patent reprieve
The U.S. Solicitor General has decided not to appeal "at this time" a district court's Aug. 3 decision that ordered the U.S. Patent and Trademark Office (PTO) to consider The Medicines Company had filed a timely application for patent term extension of Angiomax (bivalirudin).

On Aug. 6, the PTO granted a one-year interim extension of the Angiomax patent. 

On August 19, APP Pharmaceuticals, which seeks to make a generic brand of bivalirudin, filed a motion to intervene in this matter. The court has yet to hear that motion.

The patent in question is No. 5,196,404, the principal U.S. patent that covers Angiomax.

 

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup